ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
Corcept Therapeutics announced the publication of a case report in ESMO Rare Cancers detailing an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer. This prolonged clinical benefit, exceeding 105 months, highlights the potential of glucocorticoid receptor antagonism in treating difficult cancers, although this case is limited to one patient. The company continues to research relacorilant for various solid tumors, including platinum-sensitive ovarian, endometrial, cervical, pancreatic, and prostate cancers.
Form 144 CORCEPT THERAPEUTICS INC For: 16 November By Investing.com
This article announces the filing of Form 144 for Corcept Therapeutics Inc. on November 16. It includes a basic headline and mentions the company's stock symbol CORT, which was down 5.33% at the time of publication. The content is brief and primarily serves as a notification of the filing.
Form 144 CORCEPT THERAPEUTICS INC For: 16 November By Investing.com
This article reports on a Form 144 filing by CORCEPT THERAPEUTICS INC (CORT) for November 16. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article highlights the company's stock symbol CORT and its current performance of -5.10%.
Director exercises options and sells 1,500 Corcept Therapeutics (CORT) shares at $74.07.
Corcept Therapeutics Inc. director Daniel N. Swisher Jr. exercised options on November 10, 2026, to acquire 1,100 common shares at $14.08 per share and 400 shares at $10.50 per share. On the same day, he sold 1,500 common shares at $74.07 per share. This sale was conducted under a Rule 10b5-1 plan adopted on August 3, 2026, with both exercised options being fully exercisable.
Form 144 CORCEPT THERAPEUTICS INCORPORATED For: 11 November By Investing.com
This article announces the filing of Form 144 for Corcept Therapeutics Incorporated on November 11. Form 144 is a notice of the intent to sell restricted securities. The brief article provides minimal details beyond the filing announcement.
A director proposes selling 1,500 shares of Corcept Therapeutics (CORT).
Corcept Therapeutics Inc. director Daniel Swisher Jr. has reported a proposed sale of 1,500 common shares, valued at $112,537.50, with an approximate sale date of November 10, 2026. These shares were acquired through the exercise of stock options with a cash payment on the same day. The proposed sale is associated with an August 3, 2026 adoption date under Rule 10b5-1, with Morgan Stanley Smith Barney LLC acting as the broker.
Can You Justify Buying Corcept Stock Today?
Corcept Therapeutics (CORT) stock currently trades at 7.9 times its past twelve months' revenue, significantly higher than the S&P 500's 3.3 times. To maintain its current market value, Corcept would need to grow its revenue by approximately 11.9% annually for five years, based on certain assumptions about its P/E multiple and net margin. While Corcept's recent revenue growth has surpassed this required rate, its future performance and market valuation adjustments will be critical for justifying its current stock price.
Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build
Corcept Therapeutics (CORT) reported a significant jump in third-quarter net income and diluted EPS, despite a recent sharp decline in its share price. The company is perceived as undervalued by some, with a fair value estimate of $141, contingent on the success of its broader cortisol modulation pipeline beyond its single Cushing's product. However, it also faces execution risks and appears expensive on earnings multiples compared to industry averages.
Corcept Therapeutics (CORT) Stock Trades At A Premium On Strong Q3 Earnings
Corcept Therapeutics (CORT) has experienced a recent pullback despite a strong multi-year performance, prompting a re-evaluation of its stock valuation against earnings. The company's P/E ratio of 54.4x is significantly higher than the Pharmaceuticals sector average but below its peer group, suggesting a premium valuation. While Q3 2026 earnings were strong and confidence in its cortisol modulator franchise is high, analysts are divided on whether the current price is justified, with scenarios ranging from 44% undervalued to 58% overvalued depending on future growth and product line erosion.
Corcept president of oncology Vieira sells $674,068 in stock
Corcept Therapeutics Inc.'s President of Oncology, Roberto Wandenkolk Vieira, sold $674,068 worth of common stock on November 2, 2026, while also acquiring shares through stock option exercises valued at $180,242. These transactions were executed under a pre-arranged trading plan. The company recently reported strong third-quarter results, exceeding Wall Street expectations, with significant growth in both its endocrinology and oncology segments, particularly with the successful launch of Lifyorli.
25,000 Corcept Therapeutics (CORT) shares sold under Sean Maduck’s prearranged trading plan.
Sean Maduck, former President of Corcept Endocrinology, sold a total of 25,000 Corcept Therapeutics (CORT) shares on November 2 and November 3, 2026, under a Rule 10b5-1 trading plan adopted in December 2025. The sales involved exercising stock options and then selling common shares at weighted-average prices ranging from $81.4183 to $82.6756 per share, resulting in approximately $1.84 million pre-tax spread.
Corcept Therapeutics former president Sean Maduck sells $2.05M in stock
Sean Maduck, former president of Corcept Endocrinology, sold approximately $2.05 million worth of Corcept Therapeutics Inc. (NASDAQ:CORT) common stock in early November 2026, following the exercise of stock options. The sales occurred after a strong year for the biopharmaceutical company, which saw shares return 127.6% year-to-date. InvestingPro data suggests the stock is currently overvalued with a P/E ratio of 171.
Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...
Corcept Therapeutics Inc (CORT) reported strong Q3 2026 results with total revenue surging 64% year-over-year to $340.5 million, driven by robust performance in both endocrinology and the rapid adoption of its oncology drug, Lifyorli. The company reiterated its full-year 2026 revenue guidance and provided optimistic long-term projections for its Cushing's syndrome and oncology businesses, despite pending regulatory decisions and increasing market competition. Management addressed key questions regarding patient growth, drug positioning, and pipeline catalysts, emphasizing the potential for significant expansion into new indications.
Form 4 Corcept Therapeutics Incorporated: Roberto Wandenkolk Vieira (President, Oncology) For: 2 November
This article reports on a Form 4 filing for Corcept Therapeutics Incorporated, indicating insider transaction details for Roberto Wandenkolk Vieira, the President of Oncology. The filing pertains to activity on November 2nd. The article also mentions Corcept's stock symbol CORT and its price performance.
Corcept Ties $3B-$5B Cushing’s Revenue Outlook to Relacorilant
Corcept Therapeutics projects its current Cushing's syndrome business could generate at least $2 billion annually by 2030, with the potential to reach $3 billion to $5 billion if relacorilant becomes available. The FDA is expected to make a decision on relacorilant by December 17, 2026. The company also reported $340.5 million in third-quarter 2026 revenue and reaffirmed its 2026 revenue guidance of $1.1 billion to $1.2 billion.
Is Corcept Therapeutics (CORT) Cheap After Strong Earnings And BELLA Trial Results?
Corcept Therapeutics (CORT) recently reported strong third-quarter earnings, with net income reaching US$126.78 million, boosted by positive BELLA trial results for Lifyorli in platinum-resistant ovarian cancer. Despite a recent 30-day share price drop of 29.51%, the company's long-term momentum remains strong, with a 3-year return of 218.30%. The stock is currently seen as undervalued by many, with a fair value estimate of $141, driven by its expanding cortisol modulation and oncology platform.
Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics reported strong Q3 2026 results, with revenue up 64% year-over-year to $340.5 million, driven by its endocrinology business and the successful launch of ovarian cancer treatment Lifyorli. The company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion and provided updates on its clinical pipeline, including an upcoming FDA decision for relacorilant in Cushing's syndrome and progress in oncology and metabolic disease studies.
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept Therapeutics (CORT) reported strong Q3 earnings of $1.01 per share, significantly beating the Zacks Consensus Estimate of $0.68, and revenues of $340.47 million, surpassing estimates by 3.43%. The company's stock has seen a substantial gain of 131.2% year-to-date, outperforming the S&P 500. While the near-term outlook is a Zacks Rank #3 (Hold), the company's performance continues to be strong within the Medical - Drugs industry.
Corcept Therapeutics Q3 2026 Earnings Call Is Live
Corcept Therapeutics's Q3 2026 earnings call has just started, where executives will discuss financial results and answer questions from analysts. This event is crucial for CORT followers as management commentary on future demand, margins, or capital spending can significantly impact market sentiment.
Corcept Therapeutics falls on guidance despite earnings beat
Corcept Therapeutics (NASDAQ:CORT) reported strong third-quarter results, exceeding analyst expectations for both adjusted EPS ($1.01 vs. $0.79) and revenue ($340.5 million vs. $323.9 million). Despite this, shares fell 3.9% in after-hours trading because the company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion, which disappointed investors. The company saw significant growth in both endocrinology and oncology, with Lifyorli contributing $91.4 million in product revenue since its April 1st launch and a decision on relacorilant's New Drug Application expected by December 17, 2026.
Corcept Therapeutics Incorporated (CORT) Seasonal returns chart
This article provides a seasonality chart for Corcept Therapeutics Incorporated (CORT), showing its average monthly price returns from 2016 to 2026. It indicates the stock's performance trends over different periods (3Y, 5Y, 10Y, 20Y, All) and notes upcoming Q3 2026 earnings call. The current stock price and recent trading activity are also displayed.
Corcept Therapeutics Incorporated (CORT) Seasonal returns chart
This article provides a seasonal returns chart for Corcept Therapeutics Incorporated (CORT), showing its average monthly price return from 2016 to 2026. It includes current stock performance data and related market indices. The page appears to be a stub or a page with an error, as indicated by "Something went wrong."
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
Piper Sandler has reaffirmed its Buy rating on Corcept Therapeutics (CORT.US) and maintained its target price at $165. This indicates continued confidence from the analyst firm in the company's financial prospects and stock performance.
BlackRock updates its Corcept Therapeutics (CORT) stake, reporting sole voting power over 9.29M shares.
BlackRock, Inc. reported an 8.9% beneficial ownership stake in Corcept Therapeutics Incorporated (CORT) as of September 30, 2026, totaling 9,614,217 shares. The filing indicates BlackRock holds sole voting power over 9,288,025 shares and sole dispositive power over all 9,614,217 shares. This report, an amendment to a passive investment disclosure, provides details on BlackRock's control over a significant portion of Corcept's common stock.
Corcept Therapeutics Incorporated (CORT) stock price, news, quote and history
This article provides a detailed overview of Corcept Therapeutics Incorporated (CORT) stock, including its current price, market performance, and company profile. It highlights key financial metrics, analyst ratings, and the company's focus on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company's lead product, Korlym, treats hyperglycemia in Cushing's syndrome patients, and it has several other selective cortisol modulators in development.
Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Corcept Therapeutics (CORT) with a $165.00 price target, reflecting a positive outlook on the Healthcare sector stock. The company recently reported strong quarterly revenues and net profits, although corporate insider sentiment appears negative due to increased share selling. The general analyst consensus for Corcept Therapeutics is a Moderate Buy with an average price target of $141.00.
Corcept Therapeutics (CORT) Reports Positive BELLA Data, Is It Still 38% Undervalued?
Corcept Therapeutics (CORT) has reported positive Part A data from its Phase 2 BELLA trial of Lifyorli for platinum-resistant ovarian cancer, showing improved progression-free survival and response rates. Despite a recent sharp pullback in October, the company's year-to-date and three-year returns remain strong. The stock is currently viewed by many as 38% undervalued, with a fair value pegged at $141, driven by its expanding cortisol modulation portfolio beyond its single Cushing’s product.
Why Is Corcept Therapeutics Stock Trading Higher Today? - Corcept Therapeutics (NASDAQ:CORT)
Corcept Therapeutics (NASDAQ: CORT) shares are trading higher after the company reported positive findings from Part A of its Phase 2 BELLA clinical trial for Lifyorli in women with recurrent, platinum-resistant ovarian cancer. The trial demonstrated strong progression-free survival and overall response rates, especially in bevacizumab-naive patients. These results are expected to support Lifyorli's status in oncology guidelines.
A three-drug ovarian cancer treatment had a 66% response rate in patients new to one medicine.
Corcept Therapeutics announced positive results from its Phase 2 BELLA trial for Lifyorli in combination with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer. The study showed a 59% objective response rate, with responses being more pronounced (66% ORR and 8.1 months median PFS) in patients who had not previously received bevacizumab. These findings are expected to enhance Lifyorli's standing in clinical guidelines and will be presented at a medical conference next year.
Corcept Therapeutics Incorporated (CORT) stock price, news, quote and history
This article provides a comprehensive overview of Corcept Therapeutics Incorporated (CORT), including its current stock price ($87.39), recent performance, key financial statistics, and company profile. It details the biopharmaceutical company's focus on developing treatments for various disorders, highlights its product Korlym, and lists its pipeline of selective cortisol modulators. The report also includes analyst ratings, earnings trends, and a comparison of CORT's returns against the S&P 500.
Can Corcept Therapeutics Stock Rally 40% After This Dip?
Shares of Corcept Therapeutics (CORT) recently experienced a significant 29.6% dip, raising questions about a potential 40% rally. Historical data indicates that similar steep falls often lead to a recovery, with shares typically climbing over 40% within a year, though usually not maintaining that full gain by year-end. However, investors are cautioned as the company's operating margins have compressed despite rising sales, and the FDA's decision on a key drug, relacorilant, is pending in December 2026.
Can Corcept Stock Rally 40% After This Dip?
Shares of Corcept Therapeutics (CORT) recently dropped nearly 30%, prompting a look into whether the stock can achieve a 40% rally based on historical performance. Past declines of similar magnitude often resulted in gains a year later, with a median peak of 48.3% above the dip price. While the company shows accelerating revenue growth and a strong cash position, concerns remain regarding its thin operating profit margins and an upcoming FDA decision on its drug relacorilant.
Corcept Therapeutics Incorporated. Estimates – BX:HTD
This page on TradingView provides financial actuals and estimates for Corcept Therapeutics Incorporated (HTD) on the BX Swiss exchange. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.
Corcept Stock Gets A Guideline Backing Test After Diabetes Screening Endorsement
Corcept Therapeutics is seeing its investment narrative shift after the ADA and EASD issued new Type 2 diabetes management guidelines recommending screening for hypercortisolism and citing Corcept's CATALYST trial. This endorsement highlights mifepristone's role in difficult-to-control diabetes, potentially expanding the company's market beyond Cushing's disease. The challenge for Corcept will be to translate this visibility into widespread adoption while managing existing challenges like competition and funding needs.
Corcept Therapeutics Incorporated (CORT) stock price, news, quote and history
Corcept Therapeutics Incorporated (CORT) experienced a 7.55% drop in stock price to $107.50 at market close on October 22, 2026. Despite recent declines, the company shows significant long-term growth with YTD returns of 208.91% and 5-year returns of 474.25%. Analysts maintain a "Buy" rating with a target price of $165.00, reflecting optimism in its biopharmaceutical pipeline for treating severe endocrinologic, oncologic, metabolic, and neurologic disorders.
In a trial, 24% of patients with hard-to-control type 2 diabetes had excess cortisol.
A joint consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) now recommends screening adults with difficult-to-control type 2 diabetes for hypercortisolism. This recommendation is supported by Corcept Therapeutics' CATALYST trial, which found that 24% of patients with hard-to-control diabetes had excess cortisol, and that cortisol-directed therapy with mifepristone significantly reduced HbA1c levels in these patients. The report highlights the urgent need for improved screening and treatment for hypercortisolism, while also noting gaps in understanding the full role of cortisol-directed therapy.
Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
Piper Sandler analyst David Amsellem reiterated a Buy rating for Corcept Therapeutics (CORT) and set a price target of $165.00. Corcept Therapeutics reported strong quarterly revenue and net profit growth. Despite positive analyst sentiment, corporate insider activity shows a negative trend with increased selling of shares.
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
Piper Sandler has reiterated its Buy rating for Corcept Therapeutics (CORT.US), maintaining its target price at $165. This indicates continued confidence in the company's prospects from the investment bank.
Corcept Therapeutics Incorporat (CORT) Stock forecasts
Argus has issued a report on Corcept Therapeutics Inc (CORT), lowering its target price to $124.00 from a current price of $112.10. The company is described as a commercial-stage pharmaceutical firm focused on developing medications for metabolic, oncologic, and neuropsychiatric disorders by modulating cortisol's effects. The report also highlights other related company analyses by Argus.
What Corcept Therapeutics Holders Saw Early
Corcept Therapeutics shareholders saw a 40.0% return over the past year despite facing lawsuits, an FDA rejection, and new competition for its drug Korlym. Investors had to weigh a bullish outlook, supported by new study expectations and broader patient pool expansion, against a bearish one, citing concerns over declining net margins and increased R&D/SG&A costs. The company's stock currently trades at US$110, indicating that generous success odds for its pipeline are already factored into the price, while questions remain about margin pressure and competition.
Corcept Therapeutics director Wilson sells $1.15 million in shares By Investing.com
James N. Wilson, a director at Corcept Therapeutics, sold 10,000 shares of company stock for over $1.15 million on October 15, 2026, through a pre-arranged trading plan. This sale occurred after the stock surged significantly, yet InvestingPro analysis suggests it may be overvalued. Meanwhile, Corcept Therapeutics reported strong Q2 2026 results, exceeding revenue estimates and receiving upgraded price targets from analysts.
What Corcept Therapeutics Holders Saw Early
This article reviews Corcept Therapeutics' performance over the past year, highlighting the conflicting narratives investors faced regarding its stock. While the company saw significant stock price growth, supported by positive clinical developments, concerns about legal issues, competition, and declining net margins persisted. The current stock price is seen as already baking in considerable success, prompting investors to consider broader risks and explore other long-duration therapies.
Corcept Therapeutics Director James N. Wilson Sells 10,000 Shares on October 15 Under 10b5-1 Plan
James N. Wilson, a Director at Corcept Therapeutics Inc., sold 10,000 shares of the company's common stock on October 15, 2026, under a pre-established Rule 10b5-1 trading plan. The shares were sold in three separate transactions at weighted average prices ranging from $114.4751 to $116.2967, conducted indirectly through a family trust. Following these sales, the trust retains indirect ownership of 1,054,543 shares, with additional holdings in other trusts.
Form 4 Corcept Therapeutics Incorporated: James N. Wilson (Director) For: 15 October
This article reports on a Form 4 filing for Corcept Therapeutics Incorporated, indicating a transaction by Director James N. Wilson on October 15. The publication details the filing under the stock market news section. No specific transaction details are provided in the snippet.
Corcept Therapeutics director Wilson sells $1.15 million in shares By Investing.com
James N. Wilson, a director at Corcept Therapeutics, sold 10,000 shares of the company's common stock worth $1.15 million on October 15, 2026, through a pre-arranged trading plan. This sale follows a significant 151% surge in the stock over six months and a 217% year-to-date increase, although InvestingPro analysis suggests the shares may be overvalued due to a high earnings multiple. Meanwhile, Corcept Therapeutics reported strong Q2 2026 results, exceeding revenue expectations and raising its full-year outlook, leading to positive analyst ratings and price target increases.
Corcept Therapeutics director Wilson sells $1.15 million in shares
James N. Wilson, a director at Corcept Therapeutics, sold 10,000 shares of company stock for over $1.15 million on October 15, 2026, as part of a pre-arranged trading plan. This sale occurred despite the stock's significant surge of 151% over six months and 217% year-to-date, though InvestingPro analysis indicates potential overvaluation with a high earnings multiple. Concurrently, Corcept reported strong Q2 2026 results and raised its full-year revenue outlook, leading to increased price targets and Buy ratings from analysts.
A director's trust sells 10,000 shares under a trading plan at Corcept Therapeutics (CORT).
James N. Wilson, a director at Corcept Therapeutics Inc. (CORT), reported that his trust sold a total of 10,000 common shares on October 15, 2026, under a Rule 10b5-1 trading plan established on March 12, 2026. The shares were sold in three transactions at weighted average prices ranging from $114.4751 to $116.2967 per share. Following these transactions, the trust still indirectly holds over 1 million shares, along with additional shares in grantor retained annuity trusts.
Is Corcept Therapeutics (CORT) Undervalued Or Is Its Big Run Already Priced In?
Corcept Therapeutics (CORT) has seen increased options activity, particularly with a high implied volatility in a $47.50 put contract, signaling potential price fluctuations. Despite recent dips, the stock has shown significant year-to-date and five-year returns. While some analyses suggest Corcept is 18% undervalued based on a $141 fair value and its expanding cortisol modulation pipeline, a sales-based valuation indicates it trades at a high P/S ratio of 15.1x compared to industry averages, suggesting less room for multiple expansion.
Does Elevated Put Options Activity Change The Bull Case For Corcept Therapeutics Stock (CORT)?
Elevated put option activity on Corcept Therapeutics (CORT) suggests investors are re-evaluating the company's prospects due to a significant company-specific event related to its clinical and regulatory pipeline. This increased implied volatility, particularly around November 20, 2026 $47.50 put contracts, comes amidst higher earnings estimates and a top Zacks ranking. The article highlights that the primary near-term catalyst is the FDA's decision on the relacorilant NDA for Cushing's syndrome, with a PDUFA date of December 17, 2026, which is crucial for diversifying Corcept's cortisol modulation business beyond Korlym.
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock?
Options traders are showing significant interest in Corcept Therapeutics (CORT) due to high implied volatility, particularly for the November 20, 2026 $47.50 Put option. This suggests an expectation of a large price movement in the stock, potentially driven by an upcoming event. Analysts currently rate Corcept Therapeutics as a Zacks Rank #1 (Strong Buy), with recent upward revisions to earnings estimates, adding to the intrigue around the stock's potential for a significant move.